Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration

• Published in: Journal of acquired immune deficiency syndromes (1988) Vol. 5; no. 1; p. 52
• Main Authors: Clark, A G, Holodniy, M, Schwartz, D H, Katzenstein, D A, Merigan, T C
• Format: Journal Article
• Language: English
• Published: United States 1992
• Subjects: DNA, Viral - blood; Follow-Up Studies; HIV - genetics; HIV Infections - drug therapy; HIV Infections - microbiology; HIV Seropositivity - drug therapy; HIV Seropositivity - microbiology; Humans; Interleukin-2 - therapeutic use; Leukocytes, Mononuclear - microbiology; Polymerase Chain Reaction; Proviruses - genetics; Recombinant Proteins - therapeutic use; Zidovudine - therapeutic use
• ISSN: 0894-9255

Quantification of human immunodeficiency virus (HIV) proviral DNA in peripheral blood mononuclear cells (PBMC) was performed in 13 HIV-seropositive asymptomatic individuals during 10-24 months by polymerase chain reaction amplification of multiple half-log dilutions of cellular DNA. At enrollment, subjects had a geometric mean titer of 100 copies of HIV provirus per 10(6) PBMC (mean +/- SD, 2 +/- 0.9 log10). In four untreated individuals there was no significant change in provirus levels during a mean period of 13.3 months. In eight patients treated with zidovudine (ZDV) and human recombinant interleukin 2 (rIL-2), HIV provirus copies declined to 13 per 10(6) cells (1.1 +/- 0.8 log10) at the end of the first course of ZDV and rIL-2 at week 20 (p less than 0.01), and to 40 per 10(6) cells (1.6 +/- 0.9 log10) after 12 months of treatment (p less than 0.04). Subsequent courses, which included 12 weeks of ZDV alone or 4 weeks of IL-2 alone, did not significantly change the already depressed provirus copy numbers. Proviral copy number also remained depressed during drug-free "washout periods" between courses. Finally, we observed a return to a geometric mean of 400 copies per 10(6) cells (2.6 +/- 0.3 log10) a mean of 7.9 months after discontinuation of therapy. Measurement of changes in HIV provirus should provide a direct marker for defining antiviral activity of drugs, biologics, and combination therapy.